Vimarsana
Biggest News Aggregation in the World

Patrick Burnett News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrick Burnett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrick Burnett Today - Breaking & Trending Today

Frazier Life Sciences Management L.P. Has $28.31 Million Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Vimarsana News

Frazier Life Sciences Management L.P. Has $28.31 Million Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Frazier Life Sciences Management L.P. grew its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,764,232 shares of the company’s stock after buying an additional 80,000 shares during […]

Frazier Life Sciences Management L.P. Has $28.31 Million Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Vimarsana News

Frazier Life Sciences Management L.P. Has $28.31 Million Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Frazier Life Sciences Management L.P. grew its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,764,232 shares of the company’s stock after buying an additional 80,000 shares during […]

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript - Vimarsana News

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.72 EPS, expectations were $-0.65. Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript - Vimarsana News

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript February 27, 2024 Arcutis Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.72 EPS, expectations were $-0.65. Arcutis Biotherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […]

Source: yahoo.com
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% ... - Vimarsana News

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% ...

Novel steroid-free topical foam effectively controls seborrheic dermatitisOnce-daily ZORYVE® (roflumilast) topical foam, 0.3%, is approved to treat seborrheic dermatitis in individuals 9 years of age and older